



May 20, 2021

To: The Office of the Attorney General of Vermont

Via: Electronic Mail at AGO.highcostprescriptiondrugs@vermont.gov

Re: Notice of New Drug Introduction Pursuant to 18 V.S.A. § 4637 (b)

As required by 18 V.S.A. § 4637(b), Apellis Pharmaceuticals, Inc. (Apellis) is providing notice of the introduction of a new prescription drug whose Wholesale Acquisition Cost (WAC) exceeds the threshold set for a specialty drug under the Medicare Part D program. The Food & Drug Administration (FDA) approved EMPAVELI on May 14, 2021.

The new product being launched is:

Product Name	Empaveli (1080 mg/20 mL (54 mg/mL) in a single-dose vial
NDC	73606-0010-01
Date of Commercial Availability	May 18, 2021

Apellis provides this report consistent with its understanding and interpretation of 18 V.S.A. § 4637 and its provisions. In providing this notice, Apellis, reserves any and all rights or claims it may have with respect to 18 V.S.A. § 4637, the company's interpretation thereof, or the statute's application to Apellis.

Sincerely,

Michelle Cerruti

Michelle Cerruti
Director, Government Pricing